Table 1.
Mice tested | Tg− mice | Tg+ mice | ||||
---|---|---|---|---|---|---|
Included | Excluded | Included | Excluded | |||
Male | Female | n(%)1-a | Male | Female | n(%)1-a | |
Tg5469 (wt) | ||||||
4–5 Months | 21 | 18 | 2 (5) | 15 | 18 | 3 (8) |
6–12 Months | 10 | 9 | 2 (10) | 13 | 7 | 4 (17) |
Tg2576 (mutant) | ||||||
Very young | 11 | 15 | 3 (10) | 9 | 11 | 5 (20) |
Young | 15 | 19 | 4 (11) | 15 | 11 | 9 (26) |
Middle-aged | 18 | 21 | 4 (9) | 21 | 16 | 7 (16) |
Old | 22 | 13 | 4 (10) | 16 | 9 | 12 (32) |
Shown are ages, transgenotypes, genotypes, and performance competence of all mice tested. Tg2576 mice were grouped according to important stages in Aβ formation and plaque deposition: very young (4–5 months); young (6–11 months); middle-aged (12–18 months); and old (20–25 months).
Includes both genders. Number in parentheses represents percentage of all mice excluded in a given age group.